Form 4: BeOne Medicines Officer Reports Equity Transactions

Principal Accounting Officer Titus B. Ball reported the acquisition of restricted share units and the sale of American Depositary Shares for tax withholding purposes.

Summary

• Titus B. Ball, Principal Accounting Officer of BeOne Medicines Ltd., acquired 31,213 ordinary shares via restricted share units on June 11, 2026.
• The reporting person sold 169 American Depositary Shares (ADS) on June 11, 2026, to satisfy mandatory tax withholding obligations.
• Following these transactions, the reporting person holds 99,645 ordinary shares directly.
• Each ADS represents 13 ordinary shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transactions are purely administrative and related to standard executive compensation and tax compliance.

Positives

• The acquisition of 31,213 ordinary shares indicates long-term alignment through equity-based compensation.

Negatives

• The sale of 169 ADS was a mandatory transaction to cover tax liabilities, which is a standard administrative procedure rather than a discretionary market sale.

Risks

• Vesting of restricted share units is subject to continued service requirements.
• Market price volatility of American Depositary Shares could impact future tax withholding obligations.

Future Outlook

The restricted share units vest in four equal annual installments beginning June 11, 2026, subject to continued service.

Industry Context

StockSavvy.ai notes that this filing represents routine administrative activity common in the biotechnology sector, where equity-based compensation is a standard tool for executive retention.

Comparison to Industry Standards

• The use of mandatory sell-to-cover transactions for tax withholding is a standard practice among publicly traded biotech firms to manage executive tax obligations without impacting market sentiment.

Stakeholder Impact

• Minimal impact on shareholders as the transactions were related to tax withholding and did not represent a change in the officer's long-term commitment to the company.

Next Steps

• Continued service of the reporting person to satisfy vesting requirements for remaining restricted share units.

Key Dates

Keywords

BeOne Medicines, ONC, Form 4, Insider Trading, Equity Compensation, Principal Accounting Officer